FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study
FDA declined approval for MDMA as PTSD therapy, citing insufficient data and safety concerns, despite advocacy from veterans and mental health groups. Lykos Therapeutics plans to request reconsideration. This decision impacts the broader push for psychedelic treatments, with ongoing research into substances like psilocybin for mental health conditions.
Reference News
FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study
FDA declined approval for MDMA as PTSD therapy, citing insufficient data and safety concerns, despite advocacy from veterans and mental health groups. Lykos Therapeutics plans to request reconsideration. This decision impacts the broader push for psychedelic treatments, with ongoing research into substances like psilocybin for mental health conditions.